J & J’s single vaccine could help improve supply and simplify the U.S. vaccination campaign, which continues to lag behind schedule.

Johnson & Johnson said Thursday it had asked U.S. health officials to approve its single-dose COVID-19 vaccine for use in an emergency.

The drugmaker’s filing with the U.S. Food and Drug Administration (FDA) follows its January 29 report that stated the vaccine had a 66 percent infection prevention rate in its large global study.

J & J’s single-shot vaccine could help improve the offering and simplify the U.S. vaccination campaign due to concerns about the contagious UK variant of coronavirus and the potential for reduced effectiveness of the vaccine against the variant first emerging in South Africa with regard to new fluctuations.

Unlike the two currently approved vaccines from Pfizer Inc / BioNTech SE and Moderna Inc, J & Js don’t need a second shot or need to be shipped frozen.

Following the company’s request, regulators will need time to analyze the data and an advisory committee will need to meet. The company’s chief scientist said last month J&J was on track to launch the vaccine in March.

J & J’s motion raised hopes of tackling the pandemic that killed more than 451,145 Americans and more than 2,271,152 people worldwide.

Johnson & Johnson, Moderna, and Pfizer stocks have changed little in over-the-counter trading.

The US has reached an agreement to buy 100 million doses of the vaccine from J&J for $ 1 billion and the option to buy an additional 200 million doses.

The company has announced that the cans will be ready for delivery following emergency approval. The aim is to deliver one billion cans in 2021 with production in the USA, Europe, South Africa and India.

J & J’s vaccine uses a cold virus known as adenovirus type 26 to introduce coronavirus proteins into cells in the body and trigger an immune response.

The Pfizer / BioNTech and Moderna vaccines use a new technology called messenger RNA (mRNA), which requires storage in a freezer.